Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses the results of a phase II trial that examined prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses novel imaging modalities in prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase III trial measuring the efficacy of custirsen plus docetaxel versus docetaxel alone in patients with prostate cancer (SYNERGY trial).

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes a phase I/II study examining the safety and efficacy of orteronel in combination with docetaxel and prednisone in metastatic castration-resistant prostate cancer.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Future of Abiraterone Acetate

Dr. Daniel Petrylak, from Columbia University Medical Center, Discusses Chemotherapy in Prostate Cancer

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223

Dr. Daniel Petrylak from Herbert Irving Comprehensive Cancer Center Discusses Sequencing Prostate Cancer Therapies

Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials